Call Us Free: (800) 394-2767

Malvern gene therapy company targeting heart diseases raises $17M

XyloCor Therapeutics, a Malvern gene therapy company developing new cardiovascular disease treatments, has closed a $17 million series A financing.

The equity financing deal was co-led by Sofinnova Ventures in Menlo Park, Calif., and Life Sciences Partners (LSP), which is based in The Netherlands and has a office in Waltham, Mass. 

Proceeds from the financing will be used by XyloCor to advance the development of its lead product candidate, XC001, and to “expand the companies business and operational…

Source link